Articles tagged with Molecular Targets
Impact Journals will participate as an exhibitor at the AACR Annual Meeting 2023, showcasing Aging's growth in impact factor to 5.955. The meeting theme focuses on Advancing the Frontiers of Cancer Science and Medicine.
Scientists at SENS Research Foundation have discovered a new class of broad-spectrum senolytic drugs that target the key vulnerability in destructive aging cells. These drugs are effective against both primary and secondary senescent cells, making them a promising approach for treating age-related diseases.
Researchers found that dexamethasone prevents cytokine storms in severe COVID-19 patients by inhibiting ion channels and reducing immune cell inflammation. This led to improved lung function and reduced mortality rates. The study's findings provide new insights into the mechanisms of steroid treatment in severe COVID-19.
Researchers at Colorado State University have created a synthetic molecule with an asymmetric oxygen atom that remains stable and nonreactive. This feat is significant because chiral molecules can have drastically different properties and are crucial in fields like drug discovery and materials engineering.
A small molecule discovered by University of Houston researchers could potentially shorten the course of SARS-CoV-2 infection, offering a new alternative treatment option for COVID-19. The compound, CD04872SC, has shown promise in neutralizing the virus and its variants Delta and Omicron.
Scientists have engineered a unique strain of probiotic bacteria to over-express a metal transporter that binds and concentrates copper, facilitating the delivery of radionuclide therapy to cancer cells. This approach targets tumors without relying on specific receptors, making it potentially effective against treatment-resistant cancers.
A team of scientists has designed a molecule that targets the PLpro enzyme in SARS-CoV-2, limiting its replication and hampering the host's immune response. The covalent inhibitor shows promise as a new treatment for COVID-19 and other viral diseases.
Scientists have identified a new molecule that could help distinguish and treat patients with a specific subgroup of medulloblastoma, the most common malignant brain tumor in children. The discovery points to potential targeted therapies using a drug or drugs to block the molecule's activity.
The study resolves a long-standing question about the structure of respiratory supercomplexes in unicellular eukaryotic organisms. Complex II is found to be part of the supercomplex in these organisms, optimizing ATP formation and revealing a surprising variety in supercomplex construction.
A team of researchers from Syracuse University has developed a tiny, nano-sized sensor that can detect protein biomarkers in a sample at single-molecule precision. The sensor is capable of identifying and quantifying specific proteins associated with various hematological malignancies and solid tumors.
Researchers develop unsupervised machine learning algorithm to classify osteosarcoma at diagnosis based on gene expression modules. This approach enables personalized treatment strategies for osteosarcoma patients.
A new study by Tufts University researchers has identified a small molecule, Compound 350, that may help treat people with epilepsy whose condition has become resistant to traditional anti-seizure drugs. The compound was found to reduce seizure activity in rodents with drug-resistant seizures and lower brain cell death.
Researchers have identified two potential molecular targets, CSF1R and CD86, that can be used to develop CAR-T cells effective against acute myeloid leukemia. The study's findings demonstrate the potential of AI-assisted analysis in discovering new treatment options.
Researchers found that FABP5 is linked to more aggressive disease and poorer survival in multiple myeloma. Patients with higher FABP5 expression had significantly shorter time to disease progression and overall survival.
Researchers at VCU Massey Cancer Center found that simultaneous activation of Prdm16 and Smad4 proteins slows down pancreatic cancer progression. The study suggests a novel therapeutic approach to tackle this deadly disease.
Gene therapy using CRISPR-Cas9 lipid nanoparticles has been shown to be highly effective in reducing target protein expression in mice. The new delivery system increases the efficiency of in vivo gene therapy, paving the way for safe and effective treatment.
Researchers at Arizona State University describe an innovative therapy using transient expression in tobacco plants to produce a monoclonal antibody against SARS-CoV-2. This class 4 mAb provides key advantages over existing treatments, including mutation resistance and universal protection against emerging variants.
Researchers created a network of interacting proteins to understand the function of genes and link specific biological processes to diseases. They identified groups of proteins interacting with genes linked to over 1,000 human traits, providing insights into new targets for drug discovery and potential repurposing opportunities.
Researchers discovered polyphenol PCB2DG reduces inflammatory responses by inhibiting glutamine uptake in CD4+ T cells, promoting gene expression to synthesize amino acids. The study's findings offer potential for dietary polyphenol treatment of autoimmune diseases.
A new protein degrader, AK-2292, shows promise against STAT5, a key player in leukemia and other cancers. By targeting the protein's degradation, researchers have overcome previous challenges in designing small molecule inhibitors.
Scientists at the University of Illinois Chicago have found a way to selectively degrade disease-causing proteins in specific parts of cells. By studying the movement of enzymes inside cells, they discovered that attaching or detaching a fat molecule can direct where these enzymes go.
Researchers have characterised the mutually beneficial relationship between Klebsiella pneumoniae and Acinetobacter baumannii, two pathogens responsible for severe infections. This relationship enables Klebsiella to survive in higher antibiotic concentrations, making it more deadly and resistant to treatment.
The ESMO Gynaecological Cancers Congress 2023 will present the latest treatments and insights for ovarian, uterine, cervical, and rare gynaecological cancers. Around 80 studies will be presented on strategies to overcome PARP inhibitors mechanisms of resistance in ovarian cancer.
Researchers at Helmholtz-Zentrum Dresden-Rossendorf developed a new strategy to increase target molecules for radionuclide therapy in pheochromocytoma tumors, delaying tumor growth. The combination of valproic acid and decitabine prior to therapy doubled the radiation dose absorbed by the tumor.
Researchers developed new spiro-pyrazolo quinazoline derivatives with reduced bee toxicity without compromising insecticidal activity. The compounds showed promising results, including one compound with an LD50 value three to four orders of magnitude lower than fipronil.
Researchers utilized the Chemistry42 platform to generate novel molecular structures and identified a hit molecule for CDK20, a promising target for hepatocellular carcinoma. The platform's customizable reward function and generative models enabled efficient design and optimization of molecules.
Researchers evaluate an integrated NGS system, delivering accurate diagnoses in under 24 hours and expanding targeted treatments available to patients with myeloid neoplasms. The assay identified 80-92% of genetic variants, demonstrating promising results for accelerating precision therapies.
A UCF cancer researcher is studying the molecular causes of Alzheimer's disease by examining a protein deficiency in the brain. His research may lead to new targets for therapy and earlier diagnosis. The study focuses on KLF8, a protein important for brain function that has been recorded as deficient in patients with Alzheimer's.
Researchers have developed a novel catalytic approach to synthesize monocyclic 3-(pyrrol-1-yl)-azetidin-2-ones, which show potential as therapeutic agents. The method yields all four diastereomers with high selectivity and has been published in Current Organocatalysis.
New research computes first step toward predicting lifespan of electric space propulsion systems by developing a model that bridges scales between molecular dynamics simulations and experiments. The model resolves limitations and uncertainties in experimental data, gaining insight into critical phenomenon and surface morphology over time.
Researchers have discovered a new compound that could become an effective non-hormonal male contraceptive by inhibiting the CDK2 protein. The compound, named EF-4-177, showed promising results in mice, with a significant decrease in sperm counts after 28-day exposure.
A potent plant toxin called albicidin has emerged as a strong new antibiotic candidate, effective in small concentrations and highly potent against pathogenic bacteria. Its unique mechanism targets the bacterial enzyme DNA gyrase, which is essential for cell function.
Researchers used density functional theory to investigate the mechanical properties of superionic ice XVIII, which is thought to make up a large part of Neptune and Uranus. The study found that dislocations in the crystal lattice produce shear, leading to macroscopic deformations and potentially influencing the planets' magnetic fields.
Researchers successfully applied AlphaFold AI to an end-to-end platform, discovering a novel target and developing a potent hit molecule for liver cancer. The study demonstrates the potential of AI-powered drug discovery to accelerate treatment development.
A Canadian-led research team has discovered how the protein PCSK9 degrades LDL receptors, leading to increased cholesterol levels. HLA-C plays a critical role in this process, which could lead to new treatments for cardiovascular diseases and certain cancers.
Researchers have characterized the tar spot pathogen on a molecular level, revealing its virulence molecules target specific plant organelles. This study advances our understanding of plant-pathogen interactions and contributes to developing disease control strategies.
A new study standardizes the use of optical genome mapping (OGM) for patients with blood cancers, demonstrating its potential as a frontline test for diagnosing hematologic malignancies. OGM outperforms existing tests in detecting cancer-causing gene variants and identifying additional information that can improve patient outcomes.
A new prostate cancer therapy is being tested in clinical trials, targeting the treatment-resistant form of the disease. The therapy uses a drug called Abivertinib to block a specific protein that allows tumors to produce androgens, a goal of using more targeted treatments like TKIs.
A study of 184 grade I and II meningiomas found associations between specific tumor mutations and increased or decreased recurrence rates. Mutations in ATM and CREBBP were linked to accelerated recurrence, while POLE mutations showed protective effects, highlighting potential targets for intervention.
Researchers found that EWS::FLI1 induces Slit2 expression, which activates Robo receptors and enhances Ewing sarcoma growth. Silencing Slit2 strongly inhibited Ewing sarcoma cell growth, providing an opportunity for targeted therapy.
A multidisciplinary team reviews genomic test results and recommends treatment options for patients with gastrointestinal cancer, identifying clinical trials suitable for most patients. The program has been successful in providing expert treatment guidance for over 500 patients and can be a model for other cancer centers.
A team of researchers has developed an experimental method to manipulate the Rydberg state excitation in hydrogen molecules using bicircular two-color laser pulses. By controlling the photon effect and field effect, they were able to generate Rydberg states while varying the extent to which each effect contributed to the process.
Complimentary press passes are now available for Discover BMB, featuring leading experts and the latest advances in molecular life science. Qualifying journalists can register online to attend the March 25-28 event.
Researchers have created a humanized mouse model that can predict the best match for a living organ donor and detect early signs of transplant rejection. The model uses a combination of HLA-G and B regulatory cells to identify patients who may need less immunosuppressive therapy.
Researchers have developed an innovative amputated human limb model to evaluate molecularly targeted fluorescent probes for human tissues. The model allows for controlled testing of imaging agents with zero risk to patients, improving the accuracy and safety of surgical procedures.
Researchers at the University of Colorado School of Medicine have discovered a new mechanism for slowing scarring of heart tissue, a process known as cardiac fibrosis. The study's findings suggest that inhibiting the degradation of eicosanoids may be a promising approach to preventing or reversing cardiac fibrosis.
Researchers at Integral Molecular have developed highly specific antibodies against Claudin 6, a tumor-specific protein found in multiple solid tumors. The antibodies use a single atomic contact point to derive exquisite specificity, allowing them to target cancer cells while avoiding healthy tissues.
A Cornell University collaboration has made an innovative discovery by incorporating carbon dioxide into organic molecules via electrosynthesis. The team successfully created carboxylated pyridines, which are vital to medicinal chemistry, using a novel electrochemical reactor setup.
Researchers identified the molecular mechanism underlying Weiss-Kruszka syndrome, a rare neurodevelopmental disorder characterized by craniofacial anomalies and autistic features. The study reveals that the ZFP462 gene mutation leads to a failure to safeguard neural lineage specification during early embryonic development.
Researchers have made a breakthrough in precision oncology for patients with metastatic urothelial carcinoma, identifying that certain cell surface molecules decrease or are absent in these patients, making them resistant to the new drug enfortumab vedotin.
Scientists at UCSF have engineered T cells to produce a potent anti-cancer cytokine that only activates in tumor cells, eliminating melanoma and pancreatic cancer in mice. The treatment uses IL-2, which supercharges T cells to kill cancer cells while protecting against infection, offering a promising new strategy for fighting hard-to-t...
A team of researchers at Tokyo Medical and Dental University has designed and synthesized novel compounds that have the potential to be effective drugs against COVID-19. The compounds target the main protease enzyme of the SARS-CoV-2 virus, which is essential for viral replication.
Researchers at UCSF have uncovered a cellular uptake pathway important for larger molecules, enabling the creation of new drugs for cancer and other diseases. The discovery of an endogenous pathway involving interferon-induced transmembrane proteins promotes the efficient entry of diverse linked chemotypes into target cells.
Researchers at UCSF and IBM Research create a predictive model that encodes commands for cells to kill cancer cells. By combining words that guide engineered immune cells, they can predict which elements should be included in a cell to carry out precise behaviors. This advance allows scientists to rapidly design new cellular therapies.
Researchers developed a small molecule inhibitor that successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer. The drug, MRTX1133, not only targets cancer cells but also cooperates with the immune system to produce a durable response to treatment.
Scientists used AI-driven PandaOmics platform to analyze gene expression datasets from DNA repair diseases, identifying biomarkers associated with treatment response. The study focused on genes that stratify cancer patients by survival outcomes, providing potential targets for personalized therapies.
UVA researchers developed a new tool to analyze genetic data, reducing noise and bias in cancer diagnosis. The tool uses mathematical modeling to identify patterns in chromatin, helping scientists detect tiny numbers of disease cells.
Scientists at KAUST have identified dynamic regions, called cryptic binding sites, that can be targeted by drugs to treat cancer. The study reveals how molecular motion influences ligand binding to BTB domains, a critical part of many proteins involved in disease.
In a recent study, researchers targeted the POL theta enzyme to inhibit DNA production in cancer cells. The approach represents a new method for developing specific therapies for patients with BRCA1 mutations.
Scientists have discovered how cells eliminate mutated mitochondrial DNA (mtDNA) using autophagy, a cellular waste disposal process. This mechanism prevents mitochondrial damage and preserves function.